[引用][C] 1237 POSTER WIN55, 212-2 as a Potential Treatment for Estrogen-receptor Negative Breast Cancer
1237 POSTER WIN55,212-2 as a Potential Treatment for Estrogen-receptor Negative Breast
Cancer × Close The Infona portal uses cookies, ie strings of text saved by a browser on the …
Cancer × Close The Infona portal uses cookies, ie strings of text saved by a browser on the …
Abstract PD1-4: A phase I study of BKM120 and fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer
Background BKM120, a pan-Phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination
with fulvestrant (F) induced synergistic apoptotic effect in preclinical studies of estrogen …
with fulvestrant (F) induced synergistic apoptotic effect in preclinical studies of estrogen …
[PDF][PDF] Final analysis of Phase 2 study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC) demonstrates activity in patients with triple negative breast cancer …
CRC Osborne, JA O'Shaughnessy… - Am Soc Clin Oncol …, 2012 - enzon.com
Final analysis of Phase 2 study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC)
demonstrates activity in patients with Page 1 Abstract Study Design • Single agent EZN-2208 9 …
demonstrates activity in patients with Page 1 Abstract Study Design • Single agent EZN-2208 9 …
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
DJ DeFriend, A Howell, RI Nicholson, E Anderson… - Cancer research, 1994 - AACR
We have conducted a clinical trial of a novel pure antiestrogen, 7α-[9-(4, 4, 5, 5, 5-
pentafluoropentylsulfinyl) nonyl] estra-1, 3, 5,(10)-triene-3, 17 β-diol (ICI 182780), to assess …
pentafluoropentylsulfinyl) nonyl] estra-1, 3, 5,(10)-triene-3, 17 β-diol (ICI 182780), to assess …
Abstract PS18-39: estrogen receptor beta agonists for triple negative breast cancer
J Datta, N Willingham, J Manouchehri, J David… - Cancer Research, 2021 - AACR
Background: Triple negative breast cancer (TNBC) represents about 10-15% of all breast
cancers. Given the lack of targeted therapies, chemotherapy and immunotherapy are the …
cancers. Given the lack of targeted therapies, chemotherapy and immunotherapy are the …
Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).
CRC Osborne, J O'Shaughnessy, FA Holmes, HS Kim… - 2012 - ascopubs.org
1017 Background: EZN-2208 is a water-soluble PEGylated conjugate of SN38. EZN-2208
results in prolonged exposure of tumors to SN38 via preferential accumulation of EZN-2208 …
results in prolonged exposure of tumors to SN38 via preferential accumulation of EZN-2208 …
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
JD Joseph, B Darimont, W Zhou, A Arrazate, A Young… - Elife, 2016 - elifesciences.org
ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast
cancer, however, current relapse and mortality rates emphasize the need for improved …
cancer, however, current relapse and mortality rates emphasize the need for improved …
P0216IG-001 phase 4 data in Korea: Safety and efficacy
L Hwang, C Douglas, D Nam, V Trieu - European Journal of Cancer, 2014 - Elsevier
Background IG-001 was launched as Genexol-PM in Korea in February 2007, and post-
marketing surveillance for breast cancer has been completed. This was a post-marketing …
marketing surveillance for breast cancer has been completed. This was a post-marketing …
An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor–positive breast cancer
Purpose: GDC-0927 is a novel, potent, nonsteroidal, orally bioavailable, selective estrogen
receptor (ER) degrader that induces tumor regression in ER+ breast cancer xenograft …
receptor (ER) degrader that induces tumor regression in ER+ breast cancer xenograft …